Tag: Tyrosine kinase inhibitor / senolytic

  • Dasatinib

    Tyrosine kinase inhibitor / senolytic

    A multi-target tyrosine kinase inhibitor approved for chronic myeloid leukemia; repurposed in senolytic combination therapy with quercetin (D+Q).

    Abstract

    Dasatinib (BMS-354825; CAS 302962-49-8; molecular formula C22H26ClN7O2S; molecular weight 488.01) is a multi-target tyrosine kinase inhibitor developed at Bristol-Myers Squibb and approved by the FDA in 2006 under the trade name Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive ALL. The senolytic application emerged from work by Kirkland and Tchkonia at Mayo Clinic (2015 onward) demonstrating that the combination of dasatinib (targeting senescent cells of mesenchymal origin) and quercetin (targeting senescent cells of epithelial origin) selectively eliminates senescent cells while sparing healthy cells. Plasma half-life is approximately 5 hours; metabolism is via CYP3A4. Used as the canonical senolytic small molecule with clinical translation.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.